Fifty 410 review

Read the FDA letter before weighing the package discount

FDA issued warning letter 721481 to Aspen Aesthetics dba Fifty 410 concerning false or misleading claims for compounded semaglutide and tirzepatide offered on Fifty 410's website. The letter identifies the website and a matching company email, making the connection more specific than a similar business name. This is a material disclosure for someone assessing the service. It should remain part of the decision alongside the medication, care model and financial terms, rather than being obscured by an inexpensive monthly-equivalent headline.

A warning letter describes the agency's findings and required response; it does not establish that every later order has the same problem or supply a current clinical assessment of an individual patient. The useful next question is how the company explains the cited marketing and the actual preparation now proposed. Ask which clinical practice and pharmacy are responsible, what information supports the prescription and how the patient can obtain the applicable product details. A general claim about a registered pharmacy does not erase the letter or make compounded medication FDA-approved.

The advertised monthly amount is a prepaid quarter

Fifty 410's tirzepatide Starter tile pairs $133 a month with a $399 total for three months. The higher-dose tier pairs $183 with $549 for three months. Both are full-term packages divided by three, rather than flexible monthly payments at the lower amounts. A prospective patient should compare $399 or $549 as the purchase commitment and ask exactly how much medication is dispensed, how shipments are arranged and whether the same terms apply when the prescription changes.

Semaglutide appears in the company's treatment descriptions without a separate public price. Neither tirzepatide package should be assigned to it simply because both drugs are named on the website. A general starting figure elsewhere on the page likewise does not resolve the product-specific gap. Obtain one quote for the intended molecule, formulation and supply, with the complete amount due and any renewal authorization. A clear package division is useful financial information, but it cannot answer which prescription a particular buyer will receive.

Approval before payment leaves later obligations unresolved

The FAQ says no membership or subscription is required and that payment occurs only if approved. Those statements describe the opening purchase sequence; they do not promise a refund if treatment later changes or a patient chooses to stop after dispensing. No clear public cancellation policy is established. Before buying a quarter, ask what happens to unused medication, unshipped supplies and money already paid, and whether a future order requires a fresh authorization. A prepaid package can create financial exposure even without a separate membership charge.

The service also does not publish a state list. Confirm local prescribing and dispensing eligibility before completing intake, especially if a move or extended trip is expected during the purchased term. Women seeking postpartum, breastfeeding or PCOS care need to discuss the clinician's actual scope rather than infer specialization from a GLP-1 menu. Fifty 410 can only be meaningfully evaluated with its regulatory disclosure intact, the full package commitment visible and its care partners identified. The low equivalent is one part of that decision, not an adequate answer to the unresolved clinical and financial questions.